Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
2(40%)

Phase Distribution

Ph not_applicable
5
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
N/ANon-phased studies
5(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
N/A

Trials by Phase

N/A5 (100.0%)

Trials by Status

completed360%
terminated240%

Recent Activity

0 active trials
Showing 5 of 5
completednot_applicable

A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma

NCT02919670
completednot_applicable

Acceptability and Efficacy of Enterade (VS001) in Children at Risk for Environmental Enteric Dysfunction in Bangladesh

NCT05291559
terminatednot_applicable

Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency

NCT04073017
terminatednot_applicable

Safety, Acceptability, and Feasibility of Enterade®

NCT03782272
completednot_applicable

"Beverage Hydration Index" of Commercial Therapeutic Beverages

NCT03262597

Clinical Trials (5)

Showing 5 of 5 trials
NCT02919670Not Applicable

A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma

Completed
NCT05291559Not Applicable

Acceptability and Efficacy of Enterade (VS001) in Children at Risk for Environmental Enteric Dysfunction in Bangladesh

Completed
NCT04073017Not Applicable

Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency

Terminated
NCT03782272Not Applicable

Safety, Acceptability, and Feasibility of Enterade®

Terminated
NCT03262597Not Applicable

"Beverage Hydration Index" of Commercial Therapeutic Beverages

Completed

All 5 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
5